FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242199515> ?p ?o ?g. }

• W4242199515 endingPage "A455" @default.
• W4242199515 startingPage "A455" @default.
• W4242199515 abstract "Background Frontline treatment for patients with adenocarcinoma mCRPC includes docetaxel, radium 223, or the next-generation hormonal agents (NHAs) abiraterone or enzalutamide. For patients with disease progression on these therapies, approximately 20% will develop treatment-emergent neuroendocrine mCRPC (t-NE) after diagnosis of prostate adenocarcinoma. The PD-1 inhibitor pembrolizumab showed antitumor activity when combined with olaparib in cohort A of the phase 1b/2 KEYNOTE-365 trial, and the TIGIT inhibitor vibostolimab showed antitumor activity in preclinical models. Combining PD-1 and TIGIT inhibition may have enhanced benefit in adenocarcinoma mCRPC or t-NE. Methods KEYNOTE-365 is a nonrandomized, open-label, multicohort study ( NCT02861573 ) to assess several pembrolizumab combination therapies in patient populations with adenocarcinoma mCRPC or t-NE. In each of cohorts G and H, 40–100 adults with Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 who received docetaxel for mCRPC will be enrolled. Prior therapy with ≤2 NHAs and 1 other chemotherapy for adenocarcinoma mCRPC is permitted. Patients in cohort G must have adenocarcinoma of the prostate without small cell histology at study entry. Patients in cohort H must have t-NE (≥1% neuroendocrine cells in a recent biopsy specimen confirmed by central histology review) that progressed within 6 months of starting an NHA for mCRPC or hormone-sensitive prostate cancer and progressed within 6 cycles of docetaxel for mCRPC. All patients will receive MK-7684A, a coformulation of pembrolizumab 200 mg and vibostolimab 200 mg intravenously every 3 weeks until disease progression, consent withdrawal, or other discontinuation event. Adverse events will be monitored through 30 days after discontinuation (90 days if serious) and graded per CTCAE v4.0. Computed tomography or magnetic resonance imaging will be performed at screening, every 9 weeks through week 54, and every 12 weeks thereafter. Primary end points are safety and tolerability, prostate-specific antigen (PSA) response rate, and objective response rate (ORR) per RECIST v1.1 by blinded independent central review (BICR). Secondary end points are time to PSA progression, ORR and radiographic progression-free survival per Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1 by BICR; duration of response and disease control rate per RECIST v1.1 and PCWG3-modified RECIST v1.1 by BICR; and overall survival. Acknowledgements Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Trial Registration Clinicaltrials. gov, NCT02861573 Ethics Approval The study and the protocol were approved by the Institutional Review Board or ethics committee at each site." @default.
• W4242199515 created "2022-05-12" @default.
• W4242199515 creator A5012899187 @default.
• W4242199515 creator A5018436364 @default.
• W4242199515 creator A5059978899 @default.
• W4242199515 creator A5071435826 @default.
• W4242199515 creator A5072378199 @default.
• W4242199515 creator A5084909001 @default.
• W4242199515 creator A5085333470 @default.
• W4242199515 creator A5088518998 @default.
• W4242199515 date "2021-11-01" @default.
• W4242199515 modified "2023-09-25" @default.
• W4242199515 title "425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H" @default.
• W4242199515 doi "https://doi.org/10.1136/jitc-2021-sitc2021.425" @default.
• W4242199515 hasPublicationYear "2021" @default.
• W4242199515 type Work @default.
• W4242199515 citedByCount "0" @default.
• W4242199515 crossrefType "journal-article" @default.
• W4242199515 hasAuthorship W4242199515A5012899187 @default.
• W4242199515 hasAuthorship W4242199515A5018436364 @default.
• W4242199515 hasAuthorship W4242199515A5059978899 @default.
• W4242199515 hasAuthorship W4242199515A5071435826 @default.
• W4242199515 hasAuthorship W4242199515A5072378199 @default.
• W4242199515 hasAuthorship W4242199515A5084909001 @default.
• W4242199515 hasAuthorship W4242199515A5085333470 @default.
• W4242199515 hasAuthorship W4242199515A5088518998 @default.
• W4242199515 hasBestOaLocation W42421995151 @default.
• W4242199515 hasConcept C121608353 @default.
• W4242199515 hasConcept C126322002 @default.
• W4242199515 hasConcept C143998085 @default.
• W4242199515 hasConcept C2776551883 @default.
• W4242199515 hasConcept C2777701055 @default.
• W4242199515 hasConcept C2777899217 @default.
• W4242199515 hasConcept C2778971682 @default.
• W4242199515 hasConcept C2780057760 @default.
• W4242199515 hasConcept C2780192828 @default.
• W4242199515 hasConcept C2781182431 @default.
• W4242199515 hasConcept C2781190966 @default.
• W4242199515 hasConcept C61367390 @default.
• W4242199515 hasConcept C71924100 @default.
• W4242199515 hasConcept C72563966 @default.
• W4242199515 hasConceptScore W4242199515C121608353 @default.
• W4242199515 hasConceptScore W4242199515C126322002 @default.
• W4242199515 hasConceptScore W4242199515C143998085 @default.
• W4242199515 hasConceptScore W4242199515C2776551883 @default.
• W4242199515 hasConceptScore W4242199515C2777701055 @default.
• W4242199515 hasConceptScore W4242199515C2777899217 @default.
• W4242199515 hasConceptScore W4242199515C2778971682 @default.
• W4242199515 hasConceptScore W4242199515C2780057760 @default.
• W4242199515 hasConceptScore W4242199515C2780192828 @default.
• W4242199515 hasConceptScore W4242199515C2781182431 @default.
• W4242199515 hasConceptScore W4242199515C2781190966 @default.
• W4242199515 hasConceptScore W4242199515C61367390 @default.
• W4242199515 hasConceptScore W4242199515C71924100 @default.
• W4242199515 hasConceptScore W4242199515C72563966 @default.
• W4242199515 hasIssue "Suppl 3" @default.
• W4242199515 hasLocation W42421995151 @default.
• W4242199515 hasOpenAccess W4242199515 @default.
• W4242199515 hasPrimaryLocation W42421995151 @default.
• W4242199515 hasRelatedWork W122177069 @default.
• W4242199515 hasRelatedWork W1652439388 @default.
• W4242199515 hasRelatedWork W179251896 @default.
• W4242199515 hasRelatedWork W2015876133 @default.
• W4242199515 hasRelatedWork W2021751111 @default.
• W4242199515 hasRelatedWork W2135620818 @default.
• W4242199515 hasRelatedWork W2568045406 @default.
• W4242199515 hasRelatedWork W2768688864 @default.
• W4242199515 hasRelatedWork W4291017293 @default.
• W4242199515 hasRelatedWork W4297477309 @default.
• W4242199515 hasVolume "9" @default.
• W4242199515 isParatext "false" @default.
• W4242199515 isRetracted "false" @default.
• W4242199515 workType "article" @default.